NHS National Framework for Medical Retinal Vascular Treatments - 1 December 2025
key details
| Value | £1,516,353,164 (£1,819,623,796 inc. VAT) |
|---|---|
| Status | planning |
| Category (CPV) | 33600000 +1 more |
| SME suitable | Yes |
| OCID | ocds-h6vhtk-04f708 |
description
Provision of Medical Retinal Vascular Anti Veg-F and Intravitreal Corticosteroid medicines used in medical retinal vascular services for the NHS in England. To include but not limited to aflibercept, bevacizumab, brolucizumab, intravitreal dexamethasone, intravitreal fluocinolone, faricimab and ranibizumab used in the treatment of; • neovascular (wet) age-related macular degeneration (AMD) • visual impairment due to macular oedema secondary to retinal vein occlusion (branch RVO or central RVO) • proliferative diabetic retinopathy (PDR) • visual impairment due to diabetic macular oedema (DME) • visual impairment due to diabetic macular oedema (DME) who are pseudophakic or who are considered insufficiently responsive to, or unsuitable for non-corticosteroid therapy • vision impairment associated with chronic diabetic macular oedema, (DME) • visual impairment due to myopic choroidal neovascularisation (myopic CNV) • retinopathy of prematurity (ROP) with zone I (stage 1+, 2+, 3 or 3+), zone II (stage 2+ or 3+) or AP-ROP (aggressive posterior ROP) disease • inflammation of the posterior segment of the eye presenting as non-infectious uveitis • prevention of relapse in recurrent non-infectious uveitis affecting the posterior segment of the eye
notice history
1 notice published against this procurement.
| Published | Type | Regime | Notice |
|---|---|---|---|
| 21 Mar 2025 | Preliminary market engagement (UK2) | Procurement Act 2023 | 010544-2025 |
more from NHS England
- Exam Support Packages for EoE GP Registrars · £72,673 · 24 Jul 2026
- Refer a Patient - Adult ECMO 2026/27 · £99,362 · 23 Jul 2026
- Higher Specialist Scientist Training Programme (HSST) · £42,186,231 · 23 Jul 2026
- Imaging National Lecture Series · £400,000 · 22 Jul 2026
- NHS National Framework for Lenvatinib · £35,833,000 · 22 Jul 2026
- The Practice Education Facilitator role in Return to Practice · £20,000 · 22 Jul 2026
- Pharmacy Technician Clinical Skills Development · £300,000 · 22 Jul 2026
- NHS National Framework for Ferric Carboxymaltose injection · £62,633,000 · 21 Jul 2026
all contracts from this buyer →
similar contracts awarded
Other awarded contracts in the same category. Useful for seeing who normally wins this kind of work, and at what value.
- Radiopharmaceutical Products - Poltech · The Christie NHS Foundation Trust · £39,000
- NHS Branded Medicines - Tranche B - London & South of England - 1 September 2026 · NHS England · £592,363,416
- NHS National Generics Pharmaceuticals - Supply Chain Resilience · NHS England · £52,447,296
- Generic, Branded Generic & Proprietary Medicinal Products - Group 18 · Regional Business Services Organisation, Procurement and Logistics Service · £1,800,000,000
- Generic Drugs – Injections/Infusions 2 · NHS Wales Shared Services Partnership-Procurement Services (hosted by Velindre University NHS Trust) · £6,535,850
- Transitional Drugs 7 · NHS Wales Shared Services Partnership-Procurement Services (hosted by Velindre University NHS Trust) · £53,566,932
- NP90726m Vedolizumab (Entyvio®) · The Common Services Agency (more commonly known as Public Services Delivery Scotland) (PSD Scotland) · £47,898,609
- Combined Needles and Syringes Lot 1 · Secretary of State for Health and Social Care acting as part of the Crown through UK Health Security Agency · £15,264,000
source
Published on Find a Tender. Contact details for named individuals are not reproduced on this site.